Axsome Therapeutics, Inc. (AXSM) Stock Score, Valuation & Financial Research
Axsome Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.
Quick answer for AXSM
Axsome Therapeutics, Inc. currently has a Wall Street Score of 29/100. The stored market price is $220.75. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Axsome Therapeutics, Inc. does
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III tri
AXSM financial snapshot
- Wall Street Score:
- 29/100
- Current price:
- $220.75
- Market capitalization:
- $11.36B
- Revenue:
- $776.6M
- Net income:
- $-191.6M
- Free cash flow:
- $-93.9M
- Cash:
- $319.9M
- Total debt:
- $219.2M
- EPS:
- -3.75
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-93.9M, showing cash burn in the current stored period.
- The balance sheet shows $319.9M of cash versus $219.2M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: AXSM decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research AXSM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.